Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial

BACKGROUND: Recently, the combination of immunotherapy with chemotherapy has been recommended as first-line treatment of metastatic gastric/gastroesophageal junction (G/GEJ) in the clinical guidelines of many countries; the therapeutic potential of this application needs to be further investigated f...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Yuping, Lin, Yao, Yang, Ming, Lv, Jianbo, Liu, Jiaying, Wu, Ke, Liu, Ke, Li, Anshu, Shuai, Xiaoming, Cai, Kailin, Wang, Zheng, Wang, Guobin, Shen, Jianfeng, Zhang, Peng, Tao, Kaixiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491115/
https://www.ncbi.nlm.nih.gov/pubmed/36158692
http://dx.doi.org/10.3389/fonc.2022.959295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491115/
https://www.ncbi.nlm.nih.gov/pubmed/36158692
http://dx.doi.org/10.3389/fonc.2022.959295

Ejemplares similares